Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Status:
Completed
Trial end date:
2017-08-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- Test the safety of a new investigational drug called MK-8669 (ridaforolimus)
- Determine the maximum tolerated dose of MK-8669
- Determine the effectiveness of the maximum tolerated dose of MK-8669
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute